Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How long have hydroxyzine pamoate been on the market?
Alogliptin benz cost?
Dabrafenib btd date 2023?
When will a generic version of xiaflex be available?
Does lipitor's effectiveness decrease with high fat meals?

How long has myrbetriq been on the market?

See the DrugPatentWatch profile for myrbetriq

How long has Myrbetriq (mirabegron) been approved and sold?

Myrbetriq (mirabegron) is an established prescription medicine for overactive bladder. Its approval came first in the United States in 2012, which means the drug has been on the market since that year. [1]

When did Myrbetriq first reach the US market?

The U.S. Food and Drug Administration approved Myrbetriq (mirabegron) in 2012, marking the start of its commercial availability in the US. [1]

How long is that, roughly, from now?

If you’re counting from the 2012 U.S. approval year to 2026, Myrbetriq has been on the market for about 14 years. [1]

What if you mean “first available anywhere” instead of the US?

The timeline above is based on the U.S. approval/market entry. Dates can differ by country, so “how long it’s been on the market” may vary depending on which country you mean. [1]

Sources

[1] https://www.drugs.com/myrbetriq.html



Other Questions About Myrbetriq :

myrbetriq vs gemtesa cost Myrbetriq without insurance? How much is myrbetriq? Myrbetriq be generic? Generic name for myrbetriq? Cost of myrbetriq 50 mg? When did myrbetriq go generic?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated indication claim exactly matches the FDA label language for adult OAB, including both monotherapy and combination with solifenacin succinate.

Category Scores

Indication
100
Excellent

Accurate Statements

MYRBETRIQ is indicated for treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either as monotherapy or in combination with solifenacin succinate.
Label section 1.1 Adult Overactive Bladder (OAB): “MYRBETRIQ is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.” and “MYRBETRIQ, in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.”

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
Only an indication statement was evaluated; it is directly supported by the label.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
67
Visibility
78
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

established prescription medicine for overactive bladder

Core Claims
  • Myrbetriq (mirabegron) is an established prescription medicine for overactive bladder.
  • Approval came first in the United States in 2012.
  • It has been on the market since 2012.
  • From the 2012 U.S. approval year to 2026, it has been on the market for about 14 years.
  • Dates can differ by country.
Differentiators
Pricing Perception: Not Mentioned